Boehringer Ingelheim | Horse Racing Free Tips

Boehringer Ingelheim is focused on helping keep horses safe and “sound” when it comes to stress with the release of a music track specially designed to help reduce stress in horses. Research shows stress can quickly turn into equine gastric ulcer syndrome (EGUS), with one study showing horses can develop stomach ulcers in as few as five days.

The musical arrangement features soothing music designed with the horse in mind. The track was created by Janet Marlow, sound behaviorist, composer, researcher and founder of Pet Acoustics Inc. Marlow focused on creating rhythms and melodies composed for the listening comfort of the horse, including specific pitch, tone and frequencies. Studies show that playing music can help balance equine behavior because it helps mask outside sounds and vibrations, as well as provide a positive and relaxing effect.

“When Boehringer Ingelheim expressed an interest in doing something to help manage stress in horses, I was extremely interested based on my research in this area,” said Janet Marlow, founder of Pet Acoustics. “It's all about composing music and modifying the decibel and frequency levels of each note for the comfortable hearing range of the animal. Using this process, we have tested music through clinical studies at veterinary hospitals, barns, etc. to see the music elicit a release of physical tensions and stress behaviors.”

To access it, veterinarians and horse owners can visit https://www.youtube.com/channel/UCoekmWDxfuaOGuL1ELoPIGQ/videos. Visitors will be able to play the music track and video, as well as gain access to additional resources on stress, EGUS, and ways to help prevent it.

This includes information on the use of Ulcergard^® (omeprazole), to help reduce the creation of acid in a horse's stomach during times of stress, helping to maintain optimal gastric health. For ulcer prevention, horses should be given ULCERGARD once daily during these stressful periods. ULCERGARD is the only prevention for equine gastric ulcers that is proven to be safe, effective and approved by the FDA.

The post Is Your Horse Stressed? Boehringer Ingelheim Has A Special Soundtrack For Them — No, Really appeared first on Horse Racing News | Paulick Report.

Source of original post

Boehringer Ingelheim today announced the U.S. launch of the Aservo EquiHaler (ciclesonide inhalation spray), the first FDA-approved inhalant therapy for horses with severe equine asthma.

Developed after a decade of collaboration between Boehringer Ingelheim's human pharmaceutical and animal health businesses, the Aservo EquiHaler offers the promise of relief to thousands of horses that suffer from severe equine asthma, which affects 11 to 17 percent of horses.

Horses with severe equine asthma typically have clinical signs that include difficulty breathing, coughing and nasal discharge, which can have a significant impact on a horse's performance and quality of life. Over time, severely asthmatic horses may develop changes in the lung, which makes it difficult to breathe, even at rest.

“We understand the unique and inextricable link between animals and people. By delivering value through innovation, we strive to enhance the wellbeing of both and help shape the future direction of the industry,” said Caroline Belmont, Head of US Global Innovation and US Regulatory Affairs at Boehringer Ingelheim Animal Health. “We are focused on developing breakthrough therapeutics, like the Aservo EquiHaler, for animal disease areas with unmet needs to make a true impact in the lives of horses and their owners.”

The Aservo EquiHaler marks an industry first in equine medicine, as until now, there has been no FDA-approved inhalant therapy for use in horses with severe equine asthma. Severe equine asthma is an inflammatory disease of the lower airways caused by breathing in high concentrations of organic dust particles small enough to pass with air to the lower airways. Such particles are commonly found in hay and bedding.

Boehringer Ingelheim Animal Health used the Respimat inhaler, developed by the company's human pharmaceutical business, as a basis to develop the unique Soft Mist Technology of the Aservo EquiHaler, which is designed specifically for use in horses. The Aservo EquiHaler includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adapter that fits inside the nostril of the horse, allowing them to easily inhale the medicated mist into their lungs.

The active ingredient in the Aservo EquiHaler (ciclesonide inhalation spray) is ciclesonide, a glucocorticoid (steroid) that becomes activated in the lungs, which allows for the targeted delivery and activation of the medication. Studies in horses with severe asthma have demonstrated that administration of ciclesonide reversed airway obstruction associated with severe asthma, and to date, ciclesonide is the only glucocorticoid not associated with suppression of serum cortisol, a desired treatment outcome.

To learn more about Aservo EquiHaler, click here.

The post First Inhaled Therapy For Severely Asthmatic Horses Launched In U.S. appeared first on Horse Racing News | Paulick Report.

Source of original post